HRP20201523T1 - Cjepivo - Google Patents

Cjepivo Download PDF

Info

Publication number
HRP20201523T1
HRP20201523T1 HRP20201523TT HRP20201523T HRP20201523T1 HR P20201523 T1 HRP20201523 T1 HR P20201523T1 HR P20201523T T HRP20201523T T HR P20201523TT HR P20201523 T HRP20201523 T HR P20201523T HR P20201523 T1 HRP20201523 T1 HR P20201523T1
Authority
HR
Croatia
Prior art keywords
denv
virus
terminus
particle
vaccine
Prior art date
Application number
HRP20201523TT
Other languages
English (en)
Inventor
Navin Khanna
Viswanathan RAMASAMY
Original Assignee
International Centre For Genetic Engineering And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Centre For Genetic Engineering And Biotechnology filed Critical International Centre For Genetic Engineering And Biotechnology
Publication of HRP20201523T1 publication Critical patent/HRP20201523T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Claims (4)

1. Virusu slična čestica (VLP) koja sadrži: a.) rekombinantni polipeptid koji se sastoji od EDIII domene svakog od serotipova DENV-1, DENV-2, DENV-3 i DENV-4 Denga virusa povezanih sa N-krajem HBsAg, gdje su EDIII domene spojene sekvencijalno, od N-kraja prema C-kraju, u sekvenci DENV-1, DENV-3, DENV-4, DENV-2, pri čemu je aminokiselinska sekvenca EDIII domena svakog od serotipova DENV-1, DENV-2, DENV-3 i DENV-4 Denga virusa SEQ ID Br. 1, 2, 3 i 4, odnosno; kao što je prikazano na slikama 4a, b, c i d, odnosno i b.) četiri kazete za ekspresiju HBsAg polipeptida.
2. Virusu slična čestica (VLP) prema patentnom zahtjevu 1, naznačena time što rekombinantni polipeptid ima aminokiselinsku sekvencu SEQ ID Br. 11. kako je pokazano na slici 4f.
3. Cjepivo koja sadrži virusu sličnu česticu prema patentnom zahtjevu 1.
4. Cjepivo prema patentnom zahtjevu 3 za uporabu u liječenju ili sprečavanju infekcije Denga virusom.
HRP20201523TT 2014-09-01 2020-09-23 Cjepivo HRP20201523T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2478DE2014 2014-09-01
EP15775490.4A EP3188755B1 (en) 2014-09-01 2015-08-21 Vaccine
PCT/IB2015/056352 WO2016034974A1 (en) 2014-09-01 2015-08-21 Vaccine

Publications (1)

Publication Number Publication Date
HRP20201523T1 true HRP20201523T1 (hr) 2021-03-05

Family

ID=55439184

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201523TT HRP20201523T1 (hr) 2014-09-01 2020-09-23 Cjepivo

Country Status (18)

Country Link
US (3) US10189877B2 (hr)
EP (2) EP3685852A1 (hr)
JP (3) JP6983653B2 (hr)
CN (1) CN107074968B (hr)
BR (1) BR112017004008A2 (hr)
CA (1) CA2959280C (hr)
CY (1) CY1123664T1 (hr)
ES (1) ES2821480T3 (hr)
HR (1) HRP20201523T1 (hr)
HU (1) HUE053284T2 (hr)
LT (1) LT3188755T (hr)
MX (2) MX2017002621A (hr)
MY (1) MY201688A (hr)
PL (1) PL3188755T3 (hr)
PT (1) PT3188755T (hr)
RS (1) RS61000B1 (hr)
SI (1) SI3188755T1 (hr)
WO (1) WO2016034974A1 (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016034974A1 (en) * 2014-09-01 2016-03-10 International Centre For Genetic Engineering And Biotechnology Vaccine
US11793873B2 (en) 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
SG48390A1 (en) * 1991-11-16 1998-04-17 Smithkline Beecham Biolog Hybrid protein between cs from plasmodium and hbs ag
FR2741077B1 (fr) * 1995-11-14 1998-01-23 Pasteur Institut Vaccin polyvalent anti-dengue
WO2007034507A2 (en) * 2005-09-20 2007-03-29 International Centre For Genetic Engineering And Biotechnology Tetravalent dengue specific domain iii based chimeric recombinant protein
WO2008152652A2 (en) * 2007-06-12 2008-12-18 International Centre For Genetic Engineering And Biotechnology A dengue envelope domain iii-based tetravalent protein vaccine
BRPI0914012B1 (pt) * 2008-10-13 2022-02-15 Institute For Research In Biomedicine Composição farmacêutica e uso da composição farmacêutica
CN101962411B (zh) * 2009-07-24 2012-09-05 中国疾病预防控制中心病毒病预防控制所 登革病毒血清学早期诊断试剂
WO2011146933A2 (en) * 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use
CN103193870B (zh) * 2013-04-22 2014-10-22 中国人民解放军第三军医大学 一种登革病毒简并疫苗及其应用
WO2016034974A1 (en) * 2014-09-01 2016-03-10 International Centre For Genetic Engineering And Biotechnology Vaccine

Also Published As

Publication number Publication date
CA2959280C (en) 2023-09-26
JP6985458B2 (ja) 2021-12-22
PT3188755T (pt) 2020-09-29
BR112017004008A2 (pt) 2018-01-23
EP3188755B1 (en) 2020-08-05
US20210122787A1 (en) 2021-04-29
ES2821480T3 (es) 2021-04-26
MY201688A (en) 2024-03-13
WO2016034974A1 (en) 2016-03-10
JP6983653B2 (ja) 2021-12-17
US20190194261A1 (en) 2019-06-27
EP3188755A1 (en) 2017-07-12
MX2017002621A (es) 2017-07-28
CN107074968B (zh) 2021-03-12
PL3188755T3 (pl) 2021-01-25
HUE053284T2 (hu) 2021-06-28
JP2020162611A (ja) 2020-10-08
US20170240601A1 (en) 2017-08-24
JP2017526366A (ja) 2017-09-14
CN107074968A (zh) 2017-08-18
MX2021006543A (es) 2021-10-13
EP3685852A1 (en) 2020-07-29
CA2959280A1 (en) 2016-03-10
JP2022031791A (ja) 2022-02-22
US10815280B2 (en) 2020-10-27
US11945842B2 (en) 2024-04-02
CY1123664T1 (el) 2022-03-24
JP7333373B2 (ja) 2023-08-24
SI3188755T1 (sl) 2021-03-31
US10189877B2 (en) 2019-01-29
LT3188755T (lt) 2020-12-28
RS61000B1 (sr) 2020-11-30

Similar Documents

Publication Publication Date Title
JP2015524422A5 (hr)
EA201892648A1 (ru) Вирусы пичинде с трехсегментным геномом в качестве векторных вакцин
MA40880A (fr) Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
JP2017048194A5 (hr)
JP2013172734A5 (hr)
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
HRP20201523T1 (hr) Cjepivo
JP2015524421A5 (hr)
EA201390806A1 (ru) Конструкция пептидного каркаса
JP2017526689A5 (hr)
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
TW201612190A (en) Flavivirus virus like particle
WO2013001285A3 (en) Fmdv vp1 peptides
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
MX363149B (es) Vacunas de nucleoproteina de la influenza.
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
WO2014140166A3 (en) Vaccine
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
EA201890187A1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
PH12020551944A1 (en) Reverse peptide vaccine